Pomerantz LLP is investigating Dr. Reddy's Laboratories for possible securities fraud following the company's announcement of weak Q1 fiscal 2027 earnings. The earnings per share were only $0.06, impacted by a ₹2.4 billion provision related to defective semaglutide batches, which also hurt EBITDA margins. The stock price fell 9.4% on this news. The investigation will determine if Dr. Reddy's officers or directors engaged in unlawful business practices, potentially affecting investor rights and future company disclosures.
Bitcoin's 90-day correlation with gold has risen above 0.5, the highest since the 2020 stimulus period, signaling that investors are treating bitcoin more like a hard asset similar to gold. This shift comes as the US national debt surpasses $40 trill...
Faraday Future, a California-based Embodied AI company, will participate in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference in New York City on September 9-10, 2026. Jerry Wang, the company's Global Executive Chairman, w...
Lululemon has lowered its full-year sales and profit guidance again due to weak performance in China and rising competition in the U.S., expecting a 5-7% sales decline and lower earnings per share. Tesla has quietly launched its fully autonomous Cybe...
Ivanhoe Mines will release an update on its majority-owned Western Forelands Exploration Project before market open on September 8, 2026. The company will also hold an investor webinar at 10:30 a.m. Eastern Time to discuss the update, including a Q&A...
US spot Bitcoin ETFs attracted $730.9 million in net inflows on Sept. 3, marking their biggest single-day gain since January. BlackRock's iShares Bitcoin Trust led with $454 million, followed by ARK 21Shares and Fidelity funds. This surge coincided w...
